| Bioactivity | Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CLPRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research[1]. | |||||||||
| Target | IC50: 3CLPRO | |||||||||
| Invitro | 3CLPRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2.1. Without the activity of the SARS-CoV-2 3CLPRO, nonstructural proteins (including proteases) cannot be released to perform their functions, inhibiting viral replication[1]. | |||||||||
| Name | Nirmatrelvir | |||||||||
| CAS | 2628280-40-8 | |||||||||
| Formula | C23H32F3N5O4 | |||||||||
| Molar Mass | 499.53 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. KoenVandyck, et al. Considerations for the Discovery and Development of 3-Chymotrypsin-Like Cysteine Protease Inhibitors Targeting SARS-CoV-2 Infection. Current Opinion in Virology Available online 27 April 2021 |
Nirmatrelvir
CAS: 2628280-40-8 F: C23H32F3N5O4 W: 499.53
Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CLPRO) inhibitor. Nirmatrelvir (PF
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.